Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Jun 1;13(6):e0187112.
doi: 10.1371/journal.pone.0187112. eCollection 2018.

Exercise gas exchange in continuous-flow left ventricular assist device recipients

Affiliations
Clinical Trial

Exercise gas exchange in continuous-flow left ventricular assist device recipients

Alessandro Mezzani et al. PLoS One. .

Abstract

Exercise ventilation/perfusion matching in continuous-flow left ventricular assist device recipients (LVAD) has not been studied systematically. Twenty-five LVAD and two groups of 15 reduced ejection fraction chronic heart failure (HFrEF) patients with peak VO2 matched to that of LVAD (HFrEF-matched) and ≥14 ml/kg/min (HFrEF≥14), respectively, underwent cardiopulmonary exercise testing with arterial blood gas analysis, echocardiogram and venous blood sampling for renal function evaluation. Arterial-end-tidal PCO2 difference (P(a-ET)CO2) and physiological dead space-tidal volume ratio (VD/VT) were used as descriptors of alveolar and total wasted ventilation, respectively. Tricuspid annular plane systolic excursion/pulmonary artery systolic pressure ratio (TAPSE/PASP) and blood urea nitrogen/creatinine ratio were calculated in all patients and used as surrogates of right ventriculo-arterial coupling and circulating effective volume, respectively. LVAD and HFrEF-matched showed no rest-to-peak change of P(a-ET)CO2 (4.5±2.4 vs. 4.3±2.2 mm Hg and 4.1±1.4 vs. 3.8±2.5 mm Hg, respectively, both p >0.40), whereas a decrease was observed in HFrEF≥14 (6.5±3.6 vs. 2.8±2.0 mm Hg, p <0.0001). Rest-to-peak changes of P(a-ET)CO2 correlated to those of VD/VT (r = 0.70, p <0.0001). Multiple regression indicated TAPSE/PASP and blood urea nitrogen/creatinine ratio as independent predictors of peak P(a-ET)CO2. LVAD exercise gas exchange is characterized by alveolar wasted ventilation, i.e. hypoperfusion of ventilated alveoli, similar to that of advanced HFrEF patients and related to surrogates of right ventriculo-arterial coupling and circulating effective volume.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Peak arterial-end-tidal PCO2 difference, physiological dead space-tidal volume ratio and alveolar-arterial PO2 difference as a function of peak VO2 in the study population.
The prevalence of high peak P(a-ET)CO2 and peak VD/VT values in the 3 study groups testify to a trend toward high ventilation/perfusion ratio mismatch in the whole study population. Full circles, empty triangles and full triangles are LVAD, HFrEF-matched and HFrEF≥14, respectively. P(a-ET)CO2 = arterial-end-tidal PCO2 difference; VD/VT = physiological dead space-tidal volume ratio; P(A-a)O2 = alveolar-arterial PO2 difference.
Fig 2
Fig 2. Schematic summarizing ventilation/perfusion pathophysiology in left ventricular assist device recipients.
The scarce left ventricular assist device preload sensitivity constrains systemic perfusion increase during exercise causing hypoperfusion of normally ventilated alveoli, which in turn leads to an increase of wasted alveolar ventilation, ventilation/perfusion ratio and VE/VCO2 slope and to a reduction of peak VO2. This picture might be accentuated in patients with unfavorable right ventriculo-arterial coupling caused by impaired right ventricular contractility and/or increased pulmonary pressures, low circulating effective volume due to excessive diuretic use and possibly chronotropic insufficiency and increased afterload. LVAD = left ventricular assist device.

References

    1. Daneshmand MA, Rajagopal K, Lima B, Khorram N, Blue LJ, Lodge AJ, et al. Left ventricular assist device destination therapy versus extended criteria cardiac transplant. Ann Thorac Surg. 2010;89(4):1205–1209; discussion 1210. doi: 10.1016/j.athoracsur.2009.12.058 - DOI - PubMed
    1. Holman WL, Naftel DC, Eckert CE, Kormos RL, Goldstein DJ, Kirklin JK. Durability of left ventricular assist devices: Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 2006 to 2011. J. Thorac Cardiovasc Surg. 2013;146(2):437–441. doi: 10.1016/j.jtcvs.2013.02.018 - DOI - PubMed
    1. Westaby S. Rotary blood pumps as definitive treatment for severe heart failure. Future Cardiol. 2013;9(2):199–213. doi: 10.2217/fca.12.89 - DOI - PubMed
    1. Abshire M, Dennison Himmelfarb CR, Russell SD. Functional status in left ventricular assist device-supported patients: a literature review. J Card Fail. 2014;20(12):973–983. doi: 10.1016/j.cardfail.2014.08.011 - DOI - PMC - PubMed
    1. Compostella L, Russo N, Setzu T, Compostella C, Bellotto F. Exercise performance of chronic heart failure patients in the early period of support by an axial-flow left ventricular assist device as destination therapy. Artif Organs. 2014;38(5):366–373. doi: 10.1111/aor.12172 - DOI - PubMed

Publication types